Skip to main content Skip to main navigation menu Skip to site footer

Patent foramen ovale and cryptogenic stroke: still needs a complete study

  • Herlina Dimiati ,
  • Rico Rasaki ,


Abstract

Patent foramen ovale (PFO) is a residual of normal fetal anatomy. More than half of babies will develop PFO at six months of age. PFO may cause shunts from right to left, and the possibility for shunting from venous thromboembolism into the arterial circulation. Since then, many idiopathic stroke studies have been conducted, in which PFOs are often found. PFO does not require follow-up treatment in infants and children, and venous thromboembolism should also be evaluated for idiopathic stroke in young patients to assess the trend of thromboembolism associated with PFO, which affects morbidity and mortality. The decision to treat depends on the presence, size and presence of complications.

Keywords: patent foramen ovale idiopathic strokes management morbidity mortality.

References

  1. Homma S, Di Tullio MR. Patent foramen ovale and stroke. J Cardiol. 2010/06/29. 2010;56(2):134–41. Available from: https://pubmed.ncbi.nlm.nih.gov/20591626
  2. Collado FMS, Poulin M-F, Murphy JJ, Jneid H, Kavinsky CJ. Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. J Am Heart Assoc. 2018;7(12):e007146. Available from: https://pubmed.ncbi.nlm.nih.gov/29910192
  3. P. Pinto Pereira S, Nunes A, Santos C, E. Kasner S, P. L. Nunes J. The Role of Patent Foramen Ovale Closure in the Secondary Prevention of Cryptogenic Stroke: a Meta-Analysis Report. Int J Cardiovasc Sci. 2019; Available from: http://dx.doi.org/10.36660/ijcs.20190075
  4. Yuan K, Kasner SE. Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention. Stroke Vasc Neurol. 2018;3(2):84–91. Available from: https://pubmed.ncbi.nlm.nih.gov/30022802
  5. Kutty S, Sengupta PP, Khandheria BK. Patent Foramen Ovale. J Am Coll Cardiol. 2012;59(19):1665–71. Available from: http://dx.doi.org/10.1016/j.jacc.2011.09.085
  6. Agnetti A, Carano N, Sani E, Tchana B, Allegri V, Bernasconi S, et al. Cryptogenic Stroke in Children: Possible Role of Patent Foramen Ovale. Neuropediatrics. 2006;37(1):53–6. Available from: http://dx.doi.org/10.1055/s-2006-923936
  7. Pickett CA, Villines TC, Ferguson MA, Hulten EA. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials. Texas Hear Inst J. 2014;41(4):357–67. Available from: https://pubmed.ncbi.nlm.nih.gov/25120387
  8. Ntaios G, Papavasileiou V, Sagris D, Makaritsis K, Vemmos K, Steiner T, et al. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack. Stroke. 2018;49(2):412–8. Available from: http://dx.doi.org/10.1161/strokeaha.117.020030
  9. Das BB. Patent Foramen Ovale in Fetal Life, Infancy and Childhood. Med Sci (Basel, Switzerland). 2020;8(3):25. Available from: https://pubmed.ncbi.nlm.nih.gov/32630193
  10. Parrini I, Cecchi E, Forno D, Lyon AR, Asteggiano R. Device closure for patent foramen ovale in patients with cryptogenic stroke: which patients should get it? Eur Heart J Suppl. 2020;22(Suppl M):M43–50. Available from: https://pubmed.ncbi.nlm.nih.gov/33664639
  11. Hubail Z, Lemler M, Ramaciotti C, Moore J, Ikemba C. Diagnosing a Patent Foramen Ovale in Children. Stroke. 2011;42(1):98–101. Available from: http://dx.doi.org/10.1161/strokeaha.110.595876
  12. Rana BS, Thomas MR, Calvert PA, Monaghan MJ, Hildick-Smith D. Echocardiographic Evaluation of Patent Foramen Ovale Prior to Device Closure. JACC Cardiovasc Imaging. 2010;3(7):749–60. Available from: http://dx.doi.org/10.1016/j.jcmg.2010.01.007
  13. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic Stroke. Circ Res. 2017;120(3):527–40. Available from: http://dx.doi.org/10.1161/circresaha.116.308447
  14. Pristipino C, Anzola GP, Ballerini L, Bartorelli A, Cecconi M, Chessa M, et al. Management of patients with patent foramen ovale and cryptogenic stroke: A collaborative, multidisciplinary, position paper. Catheter Cardiovasc Interv. 2013;82(1):E38–51. Available from: http://dx.doi.org/10.1002/ccd.24637
  15. Abdelghani M, El-Shedoudy SAO, Nassif M, Bouma BJ, de Winter RJ. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology. 2019;143(1–2):62–72. Available from: http://dx.doi.org/10.1159/000501028
  16. Valencia-Sanchez C, Fortuin FD, Sweeney JP, Ingall TJ, Marks LA, Wingerchuk DM, et al. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke? Neurologist. 2018;23(5):175–80. Available from: http://dx.doi.org/10.1097/nrl.0000000000000200
  17. Kottoor SJ, Arora RR. Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close? J Cent Nerv Syst Dis. 2018;10:1179573518819476–1179573518819476. Available from: https://pubmed.ncbi.nlm.nih.gov/30574006
  18. Saver JL. Cryptogenic Stroke. N Engl J Med. 2016;374(21):2065–74. Available from: http://dx.doi.org/10.1056/nejmcp1503946
  19. Bang OY, Lee MJ, Ryoo S, Kim SJ, Kim JW. Patent Foramen Ovale and Stroke-Current Status. J stroke. 2015/09/30. 2015;17(3):229–37. Available from: https://pubmed.ncbi.nlm.nih.gov/26437990
  20. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2011/12/15. 2012;43(2):422–31. Available from: https://pubmed.ncbi.nlm.nih.gov/22180252
  21. Chun K-J. Patent Foramen Ovale and Cryptogenic Stroke. Korean Circ J. 2008;38(12):631. Available from: http://dx.doi.org/10.4070/kcj.2008.38.12.631
  22. Niu X, Ou-Yang G, Yan P, Huang S, Zhang Z, Zhang Z. Closure of patent foramen ovale for cryptogenic stroke patients: an updated systematic review and meta-analysis of randomized trials. J Neurol. 2018;265(6):1259–68. Available from: http://dx.doi.org/10.1007/s00415-018-8766-2
  23. Sagris D, Georgiopoulos G, Perlepe K, Pateras K, Korompoki E, Makaritsis K, et al. Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. Stroke. 2019;50(11):3135–40. Available from: http://dx.doi.org/10.1161/strokeaha.119.026512
  24. Mojadidi MK, Zaman MO, Elgendy IY, Mahmoud AN, Patel NK, Agarwal N, et al. Cryptogenic Stroke and Patent Foramen Ovale. J Am Coll Cardiol. 2018;71(9):1035–43. Available from: http://dx.doi.org/10.1016/j.jacc.2017.12.059
  25. Oto A, Aytemir K, Özkutlu S, Kaya EB, Yorgun H, Canpolat U, et al. Transthoracic Echocardiography Guidance during Percutaneous Closure of Patent Foramen Ovale. Echocardiography. 2011;28(10):1074–80. Available from: http://dx.doi.org/10.1111/j.1540-8175.2011.01524.x
  26. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale. N Engl J Med. 2012;366(11):991–9. Available from: http://dx.doi.org/10.1056/nejmoa1009639
  27. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism. N Engl J Med. 2013;368(12):1083–91. Available from: http://dx.doi.org/10.1056/nejmoa1211716
  28. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al. Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. N Engl J Med. 2013;368(12):1092–100. Available from: http://dx.doi.org/10.1056/nejmoa1301440
  29. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017;377(11):1022–32. Available from: http://dx.doi.org/10.1056/nejmoa1610057
  30. Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017;377(11):1011–21. Available from: http://dx.doi.org/10.1056/nejmoa1705915
  31. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017;377(11):1033–42. Available from: http://dx.doi.org/10.1056/nejmoa1707404
  32. Varotto L, Bregolin G, Paccanaro M, De Boni A, Bonanno C, Perini F. The Closure of Patent Foramen Ovale in Preventing Subsequent Neurological Events: A Bayesian Network Meta-Analysis to Identify the Best Device. Cerebrovasc Dis. 2020;49(2):124–34. Available from: http://dx.doi.org/10.1159/000507317

How to Cite

Dimiati, H., & Rasaki, R. (2021). Patent foramen ovale and cryptogenic stroke: still needs a complete study. Bali Medical Journal, 10(2), 663–667. https://doi.org/10.15562/bmj.v10i2.2529
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
15

Share

Search Panel

Herlina Dimiati
Google Scholar
Pubmed
BMJ Journal

Rico Rasaki
Google Scholar
Pubmed
BMJ Journal